Literature DB >> 351058

Immunochemistry of Salmonella O-antigens: preparation of an octasaccharide-bovine serum albumin immunogen representative of Salmonella serogroup B O-antigen and characterization of the antibody response.

S B Svenson, A A Lindberg.   

Abstract

The O-antigenic polysaccharide of phenol-water extracted Salmonella typhimurium (O antigens 4, 12) lipopolysaccharide was enzymatically cleaved by phage P22 endorhamnosidase. An octasaccharide with the (formula: see text) structure Gal-Man-Rha-Gal-Man-Rha was isolated and shown to retain the O-antigen 4 specificity of the native polysaccharide. After oxidation of the terminal reducing rhamnose residue to the corresponding aldonic acid, the octasaccharide was covalently linked to bovine serum albumin (OLS-BSA) by use of a water-soluble carbodimide. The resulting conjugate showed O-antigen 4 specificity in enzyme-linked immunosorbent assay (ELISA) ans passive hemagglutination inhibition tests. Immunization of rabbits with the OLS-BSA conjugate gave rise to antibodies directed toward both the octasaccharide and the carrier protein. ELISA titration with synthetic disaccharide-protein conjugates as antigens revealed that the antibody titer against the mannose-rhamnose structure was higher than against the abequose-mannose structure. In rabbits immunized with heat-killed whole bacteria the titers against the two disaccharides were equal. The reason for this difference is not obvious. It is evident, however, that the OLS-BSA conjugate elicited in rabbits O-antibodies with the same specificity as whole bacteria.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 351058

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  A sulfhydryl-rich IgM protein with multiple serological specificities.

Authors:  G Merlini; O Zettervall; A Forsgren; M Galliano; A A Lindberg; S B Svenson; F Pavesi; I Turesson
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

2.  The effect of a bacterial endotoxin or cloprostenol on the clinical status and hormonal levels in 80-100 days pregnant gilts.

Authors:  N Cort; H Kindahl
Journal:  Acta Vet Scand       Date:  1986       Impact factor: 1.695

3.  A caprine experimental model for studies on inflammation.

Authors:  K Persson; G Aström
Journal:  Vet Res Commun       Date:  1995       Impact factor: 2.459

4.  Effects of prostaglandin E2, prostaglandin F2 alpha and endotoxin on plasma calcium levels in the goat.

Authors:  G Fredriksson; H Kindahl; L E Edqvist
Journal:  Acta Vet Scand       Date:  1984       Impact factor: 1.695

5.  Some reproductive and clinical aspects of endotoxins in cows with special emphasis on the role of prostaglandins.

Authors:  G Fredriksson
Journal:  Acta Vet Scand       Date:  1984       Impact factor: 1.695

6.  Correlation of the duration and magnitude of protection against Salmonella infection afforded by various vaccines with antibody titers.

Authors:  C R Angerman; T K Eisenstein
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

7.  Endotoxin-induced abortion in early pregnant gilts and its prevention by flunixin meglumine.

Authors:  N Cort; H Kindahl
Journal:  Acta Vet Scand       Date:  1990       Impact factor: 1.695

8.  Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice.

Authors:  S B Svenson; A A Lindberg
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

9.  Prevention of renal scarring from pyelonephritis in nonhuman primates by vaccination with a synthetic Escherichia coli serotype O8 oligosaccharide-protein conjugate.

Authors:  J A Roberts; M B Kaack; G Baskin; S B Svenson
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

10.  Induction of endotoxin tolerance with nonpyrogenic O-antigenic oligosaccharide-protein conjugates.

Authors:  A A Lindberg; S E Greisman; S B Svenson
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.